RK

Ravi Katkuri

Active Director Director DIN 10187730
DIN 10187730 First appointment Jun 2023 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jun 2023
Shareholding value •••• Premium profile

About Ravi Katkuri

Data last updated:

Ravi Katkuri is a Director at Priscilla Lifesciences Private Limited (since 2023). The company operates in Pharma. Priscilla Lifesciences Private Limited reported revenue of ₹9.9 Lakh (FY 2024).

DIN 10187730
Primary Designation Director
Industry Pharma
First Appointment 01 Jun 2023
Oldest Company Age 3 yrs
Largest company Priscilla Lifesciences Private Limited · ₹9.9 Lakh (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director01 Jun 20232023₹9.9 Lakh (FY 2024)Active

Board colleagues of Ravi Katkuri

NameDINCompanyDesignation
Naresh Boddupally10187729Priscilla Lifesciences Private LimitedDirector

Directorship timeline

Open interactive timeline →
Priscilla Lifesciences Private Limited
Premium access

Shareholding and investment profile for Ravi Katkuri

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ravi Katkuri

Ravi Katkuri currently holds 1 directorship: Priscilla Lifesciences Private Limited (Director, since 01 Jun 2023, revenue ₹9.9 Lakh (FY 2024)).

Ravi Katkuri was first appointed on 01 Jun 2023 as Director at Priscilla Lifesciences Private Limited.

The current boards of Ravi Katkuri's companies include Naresh Boddupally (Priscilla Lifesciences Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available